COLL — Collegium Pharmaceutical, Inc.

Summary of Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Full-Year 2025 Results:

  • Net Revenues: $780.6 million, up 24% year-over-year.
  • Adjusted EBITDA: $460.5 million, up 15% year-over-year.
  • Operating Cash Flows: $329.3 million.
  • Cash Position: $386.7 million in cash and marketable securities, up $224 million from 2024.
  • Net Income: $62.9 million, down 9% year-over-year, impacted by a one-time loss on debt extinguishment of approximately $16 million.
  • Earnings Per Share: GAAP EPS of $1.98 (basic), down from $2.14; Non-GAAP adjusted EPS of $7.42, up from $6.45.

• Q4 2025 Results:

  • Total Net Product Revenues: $205.4 million, up 13% year-over-year.
  • Jornay PM Revenue: $45.9 million, up 57% year-over-year; $148.9 million for the full year, up 48%.
  • Pain Portfolio Revenue: $631.7 million for the year, up 6%.

2. Strategic Updates and Business Highlights

• Jornay PM Growth: Continued momentum with a 20% increase in prescriptions year-over-year, reaching an all-time high of over 29,000 prescribers.
• Pain Portfolio Performance: All three core pain medicines showed growth, contributing to revenue stability.
• Capital Deployment: Successfully closed a $980 million syndicated credit facility, enhancing financial flexibility and reducing interest costs.
• Share Repurchase Program: $25 million repurchased in 2025, with $150 million remaining in the authorized program.
• ESG Commitment: Released a 2025 ESG report highlighting community support initiatives.

3. Forward Guidance and Outlook

• 2026 Financial Guidance:
  • Total Product Revenues: Expected between $805 million and $825 million, reflecting a 4% increase year-over-year.
  • Jornay Revenue: Projected at $190 million to $200 million, representing over 30% growth.
  • Adjusted EBITDA: Expected between $455 million and $475 million, a modest increase year-over-year.
• Market Dynamics: Anticipate typical first-quarter revenue declines due to annual deductible resets impacting patient costs.

4. Bad News, Challenges, or Points of Concern

• Net Income Decline: GAAP net income decreased due to one-time debt extinguishment costs.
• Potential Competitive Pressures: While no immediate threats to Jornay PM were identified, ongoing monitoring of market dynamics is crucial.
• Operating Expense Increases: GAAP operating expenses rose 37% year-over-year, primarily due to investments in Jornay commercialization and sales force expansion.

5. Notable Q&A Insights

• Jornay Guidance Assumptions: Growth is expected to be driven by demand, with stable gross-to-net ratios.
• Competitive Landscape: No significant competitive developments noted that could impact Jornay demand.
• Sales Force Strategy: Current sales force of 180 is deemed appropriate, with potential for future expansion based on market dynamics.
• Nucynta AG Impact: Belbuca and Xtampza are considered promotionally sensitive, and the company plans to maintain investment in these products despite potential generic competition.

This summary encapsulates the key takeaways from Collegium Pharmaceutical's Q4 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.